---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-107906"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:39:52.192532+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics raises $100M in public offering to fund TARA-002 clinical development

## Summary
- Gross proceeds of ~$100M from offering of 13.69M shares and 2.33M pre-funded warrants at $6.25/share.
- Proceeds to fund clinical development of TARA-002 for cancer and rare diseases; also working capital.
- Underwriters granted 30-day option to purchase up to 2.4M additional shares; company and insiders have 60-day lock-up.
- Offering closed December 11, 2024; TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., Scotiabank acted as joint book-runners.
- Pre-funded warrants exercisable at $0.001, with ownership limitation of 4.99% (adjustable to 19.99%).

## SEC filing metadata
- accession: 0001213900-24-107906
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390024107906/0001213900-24-107906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390024107906/ea0224389-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-107906
- JSON: https://secwatch.observer/filing/0001213900-24-107906.json
- Plain text: https://secwatch.observer/filing/0001213900-24-107906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.